Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to find the highest dose of the investigational drug STK-012 that can be given safely in combination with pembrolizumab immunotherapy to people with solid tumors that have spread or come back despite prior treatment. STK-012 is a modified form of a protein called interleukin-2, which is normally made by the immune system. It may help to multiply and activate tumor-killing cells of the immune system.
Researchers are assessing different doses of TNG462 to give with daraxonrasib or zoldonrasib in people with advanced cancer. The people in this study have pancreatic cancer or non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their cancers have a mutation (change) in the RAS gene and are missing a protein called MTAP.
Researchers want to find the best doses of abemaciclib and cabozantinib to use in people with advanced kidney cancer. The people in this study have clear cell renal cell carcinoma that metastasized (spread); they previously received other kidney cancer therapies. In addition, their cancer keeps growing even after 2 or 3 prior treatments, including checkpoint inhibitor immunotherapy.
Researchers want to find the best dose of ADCE-D01 to treat soft tissue sarcoma. In this study, we treat people with soft tissue sarcoma that is inoperable (cannot be surgically removed) or metastasized (spread).
Researchers want to see how well enfortumab vedotin works in people with adenoid cystic carcinoma. This cancer most often starts in the salivary glands and certain other glands in the body. The people in this study have adenoid cystic cancer that came back or spread after treatment.
Researchers are expanding access to the drug zidesamtinib for people with advanced solid tumors. The people in this study have non-small cell lung cancer (NSCLC) or another solid tumor with a fusion (change) in the ROS1 gene. This fusion can cause cancer cells to multiply and spread.
For people with newly diagnosed acute myeloid leukemia (AML), the more leukemia cells are destroyed, the better their long-term outcomes. In this study, researchers want to see adding venetoclax to standard chemotherapy (daunorubicin/cytarabine) or giving it with azacitidine works better than standard therapy for getting rid of the small amount of remaining leukemia cells. The people in this study include young adults with intermediate-risk AML.
Researchers are assessing GC012F (AZD0120) in people with multiple myeloma that came back or keeps growing after treatment. In the first part of this study, researchers will find the best dose of GC012F to use in patients. In the second part of the study, they will assess this dose to treat advanced multiple myeloma.
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
Autologous stem cell transplant (ASCT) is a standard treatment for multiple myeloma. An ASCT replaces the blood-forming cells destroyed by disease or treatment with healthy cells collected from your blood. Before ASCT, people generally receive a standard drug, melphalan, to prepare the body for the transplant.
